The broader efficacy trials inform of demonstration projects are usually requested by regulators before licencing the project. Our community would really want to take up the scale up but most likely will be affected by the limited resources that are allocated for the health sector. Our budget costing is very poor that most of the health services in the country are supported by development partners.Therefore this might require a lot of re- organisation inform of allocation of resources both financial and human to facilitate the move to to scaling up of the process.There is need to build a strong base for product acceptability.This will require engagement efforts to create a base of supporters and advocates for eventual uptake of the product.
At this level the policy makers are very important in this stage so that they influence the policy process towards implementation of the new product.
We have shared results with stakeholders before, it is a good experience and every time it is done you learn a how to do it better the next time you have the opportunity. However it is important to note that a site needs to have a dissemination plan to facilitate its stakeholder engagements. When the results are ready it is a primary responsibility of the Principal Investigator to inform the key stakeholders about the results of the completed research.
Arrangements are done, to include the information that is planed to be shared by the stakeholders and this information is reviewed before it is shared to the public.All stakeholders who were engaged at the start of the study should be engaged at this stage of results dissemination. Appropriate messages are developed, approved and eventually shared with the different audiences.It is critical that information is first shared with the study participants so they don’t get to hear about it from other sources other than he research team.
During the dissemination a team should be identified to handle the communication and should be lead by the PI.This helps to avoid giving uncoordinated information to stakeholders.
Our site has not been involved in sharing large trial results, but with the experience drawn from the phase one / two trials we can ably share the large trial results.
